1-1 of 1
Tobias M. Kohl, PhD
Close
Sort by
Journal Articles

ABT-737 Neutralizes Resistance to FLT3 Inhibitor Treatment Mediated by Overexpression of BCL2 in Primary AML Blasts.

Tobias M. Kohl, PhD, Christine Hellinger, Wolfgang Hiddemann, MD, PhD, Stefan K. Bohlander, MD, Karsten Spiekermann, MD
Journal: Blood
Blood (2006) 108 (11): 524.
https://doi.org/10.1182/blood.V108.11.524.524
Published: 2006